Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 17, 2026, provides a clinical trial update regarding camlipixant, a P2X3 receptor antagonist. The report focuses on the results of the CALM-1 and CALM-2 Phase III trials for refractory chronic cough (RCC).
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a clinical update rather than a financial results report.
Material Changes and Clinical Outcomes
- CALM-1 Trial: Met its primary endpoint. Camlipixant 50mg twice daily showed statistically significant reductions in 24-hour cough frequency versus placebo at week 12.
- CALM-2 Trial: Did not reach statistical significance for the primary endpoint with 50mg twice daily at week 24.
- Lower Dose: Camlipixant 25mg twice daily failed to reach statistical significance in either study.
- Secondary Endpoints: Key measures, including the Chronic Cough Diary (CCD), did not meet target thresholds in either study.
- Safety Profile: The overall incidence and severity of treatment-related adverse events were similar between camlipixant and placebo groups across both trials.
Outlook, Management Commentary, and Risks
Based on aggregate data, GSK management concluded that the limited efficacy demonstrated is unlikely to transform patient care. Consequently, GSK has decided not to progress further development of camlipixant for RCC. Results will be submitted for future publication to contribute to scientific understanding.
Development of camlipixant will continue in other indications; specifically, the Phase IIb BALANCE trial (NCT07519395) will proceed to evaluate efficacy and safety in adults with irritable bowel syndrome - diarrhoea (IBS-D) and irritable bowel syndrome - mixed (IBS-M).
The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the 2025 Form 20-F and Q1 2026 results.
Key Facts for Investor Verification
- Discontinuation of camlipixant development for refractory chronic cough (RCC).
- Continuation of camlipixant development for IBS-D and IBS-M via the BALANCE trial.
- Confirmation that safety profiles remained consistent with placebo despite efficacy failures in the longer-term trial.
- Impact of this clinical setback on the broader respiratory pipeline and R&D expense guidance (not detailed in this text).